zanubrutinib + polatuzumab vedotin + rituximab

The ZPR regimen is a chemotherapy-free combination therapy consisting of zanubrutinib, polatuzumab vedotin, and rituximab. Zanubrutinib is a potent, highly selective small-molecule inhibitor of Bruton's tyrosine kinase (BTK) that covalently binds to the enzyme, blocking B-cell receptor signaling and inhibiting B-cell proliferation. Polatuzumab vedotin is an antibody-drug conjugate (ADC) targeting CD79b, a component of the B-cell receptor complex; it delivers the cytotoxic microtubule inhibitor monomethyl auristatin E (MMAE) directly into malignant B-cells. Rituximab is a chimeric monoclonal antibody targeting the CD20 antigen on the surface of B-lymphocytes, inducing cell death through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This regimen is being investigated by Dr. Peng Liu at Zhongshan Hospital, Fudan University, as a treatment option for elderly patients with treatment-naive or relapsed/refractory diffuse large B-cell lymphoma (DLBCL), aiming to balance efficacy with a manageable safety profile in frail populations.

Other names

ZPR regimenZanubrutinib, Polatuzumab vedotin and Rituximab